GILEAD SCIENCES, INC.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Gilead Sciences develops and markets pharmaceuticals focused on treating HIV/AIDS, viral hepatitis (B and C), COVID-19, and certain cancers. Its products include Biktarvy and Descovy for HIV treatment and prevention, and Veklury (remdesivir) for COVID-19.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
| Member | Chamber | Type | Amount | Date |
|---|---|---|---|---|
| Jared MoskowitzFL23 | House | Buy | $1,001 - $15,000 | May 6, 2026 |
| Alan ArmstrongArmstrong, Alan (Senator) | Senate | Buy | $1,001 - $15,000 | Mar 27, 2026 |
| Thomas H TubervilleTuberville, Tommy (Senator) | Senate | Buy | $1,001 - $15,000 | May 10, 2024 |
| Thomas H TubervilleTuberville, Tommy (Senator) | Senate | Sell | $1,001 - $15,000 | May 8, 2024 |
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable GILD activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.